The ABC's of Carcinoid and Neuroendocrine Tumors
Three of the world’s leading carcinoid and NET cancer specialists – Dr. Richard R.P. Warner, Dr. Edward M. Wolin, and Dr. Eugene A. Woltering – talk about the advice they offer their patients, the advances they have seen during their careers, and what they anticipate will be available for NET patients in the future. (Click on the words YouTube in the bottom right of the video to see it in a larger size).
The Latest News
New England Journal of Medicine Publishes Article on PRRT Clinical Study for Neuroendocrine Tumors
One of the most prestigious medical journals in the United States, the New England Journal of Medicine, has just published an article (January 12, 2017 issue) about the results of the NETTER-1 Phase 3 clinical trial results evaluating the efficacy and safety of Lutetium-177-Dotatate for patients with advanced, progressive somatostatin receptor-positive midgut neuroendocrine tumors. Shedding light on PRRT, peptide receptor radionuclide therapy! Click here to read more
April Luncheon with the Experts in White Plains, NY — Carcinoid and Neuroendocrine Tumor Patients Are Invited!
The Big Apple NETs support group invites you to join fellow carcinoid and neuroendocrine tumor (NET) patients and 3 medical experts for Lunch with the Experts on Sunday, April 2, 2017 at the Westchester Hills Golf Club in White Plains, New York. This is a unique opportunity to share experiences with other patients and to hear from physicians who specialize in NET treatment, in an informal setting. Read more and make your reservations
Speaking Up: What Stands in the Way of Patient-Physician Conversation about Neuroendocrine Tumors and Carcinoid Syndrome
Members of the neuroendocrine tumor (NET) community are invited to attend an informal discussion, hosted by Lexicon Pharmaceuticals, about the barriers and opportunities in discussing NETs and carcinoid syndrome with your healthcare professional team. The event will take place on January 20 in San Francisco. The panelists are Josh Mailman; George Fisher, MD; Giovanna Imbesi; Eric Liu, MD; and Richard Redding. Click here for the event flyer and to RSVP
Recent Progress in Neuroendocrine Tumor Management
Has there been significant recent progress in the management of Neuroendocrine Tumors? NET specialist Jonathan R. Strosberg, MD of the H. Lee Moffitt Cancer Center in Tampa, Florida, says “unequivocally yes.” OncLive interviews Dr. Strosberg on the progress in the treatment landscape. Read more
NETSPOT Gallium-68 Code for Medicare/Medicaid and Private Payors
Another exciting step forward for the NET community! Advanced Accelerator Applications announced that the Centers for Medicare & Medicaid Services (CMS) has granted NETSPOT® Transitional Pass-Through Status under an “A-code” (A9587) for drug reimbursement, effective January 1, 2017. What this means is that the different institutions doing the Gallium-68 scan utilizing NETSPOT® now have a reimbursement code to submit to Medicare/Medicaid and private payors. While it does not guarantee that individual patients will get insurance coverage, this is a very positive step for getting more institutions to offer the Gallium-68 scan. To read the Advanced Accelerator Applications press release, click here: http://bit.ly/2hf8Sjr.
Reaching Those Who Are Still Undiagnosed
To combat statistics showing that it often takes 5 to 7 years for patients to receive the correct diagnosis of a neuroendocrine tumor (NET), the Carcinoid Cancer Foundation has partnered with Advanced Accelerator Applications to create an infographic listing common symptoms and misdiagnoses. Please share this broadly in hopes of helping others get the proper diagnosis more quickly. Download the infographic here.
FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors
Breaking news on June 1, 2016 from the U.S. Food and Drug Administration! The FDA has approved NETSPOT, “the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging.” Read more from the FDA and Read more from Advanced Acclerator Applications
One Step Closer in the US to Peptide Receptor Radionuclide Therapy, PRRT, for Neuroendocrine Cancers
The clock is ticking!! With Advanced Accelerator Applications’ completed New Drug Application (NDA) submission of Lutathera to the U.S. Food and Drug Administration during the week of April 25, 2016, a decision from the FDA is expected in early 2017. Additionally, an Expanded Access Program (EAP) in the United States for the investigational product, Lutathera, has begun at a few institutions across the country. Read more